Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review
AbstractConformational diseases represent a new aspect of proteomic medicine where diagnostic and therapeutic paradigms are evolving. In this context, the early biomarkers for target cell failure (neurons, β-cells, etc.) represent a challenge to translational medicine and play a multidimensional role as biomarkers and potential therapeutic targets. This systematic review, which follows the PICO and Prisma methods, analyses this new-fangled multidimensionality, its strengths and limitations, and presents the future possibilities it opens up. The nuclear diagnosis methods are immunoassays: ELISA, immunodot, western blot, etc., while the therapeutic approach is focused on pharmaco- and molecular chaperones. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Avila-Vazquez, M.F.; Altamirano-Bustamante, N.F.; Altamirano-Bustamante, M.M. Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review. Molecules 2018, 23, 79.
Avila-Vazquez MF, Altamirano-Bustamante NF, Altamirano-Bustamante MM. Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review. Molecules. 2018; 23(1):79.Chicago/Turabian Style
Avila-Vazquez, Maria F.; Altamirano-Bustamante, Nelly F.; Altamirano-Bustamante, Myriam M. 2018. "Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review." Molecules 23, no. 1: 79.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.